Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib with or without lomustine versus lomustine in recurrent glioblastoma
2007-000383-24Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of cediranib in glioblastoma (GBM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Progression-free survival. Started Aug 2007; status: completed.
02
Drugs
cediranib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2007-000383-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000383-24.